CABIO(SH:688089)2025-10-15 08:20Financial Performance - For the first three quarters of 2025, the company expects to achieve revenue of approximately 428 million yuan, representing a year-on-year growth of 10.55%[3] - The net profit attributable to the parent company for the same period is projected to be around 129 million yuan, reflecting a significant increase of 53.77% year-on-year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses is estimated at approximately 115 million yuan, marking a year-on-year growth of 75.41%[3] - In the same period of 2024, the company reported revenue of 387 million yuan and a net profit of 83.89 million yuan[5] - The earnings per share for the first three quarters of 2024 was 0.50 yuan per share[5] Revenue Drivers - The increase in revenue is primarily driven by higher sales of ARA and DHA products to domestic customers[7] - Profit growth is attributed to increased revenue, improved production efficiency, and optimized product and customer structures[7] Forecast and Uncertainties - The financial data for this forecast has not been audited by registered accountants and is based on preliminary calculations by the finance department[4] - Investors are advised to note that the forecast data is subject to change and the final figures will be disclosed in the official Q3 2025 report[9] - The company has not identified any significant uncertainties that could affect the accuracy of this earnings forecast[8]